PMID- 29516917
OWN - NLM
STAT- MEDLINE
DCOM- 20180830
LR  - 20220316
IS  - 1998-4138 (Electronic)
IS  - 1998-4138 (Linking)
VI  - 14
IP  - 2
DP  - 2018 Jan-Mar
TI  - Upregulation of CXC chemokine receptor 4-CXC chemokine ligand 12 axis ininvasive 
      breast carcinoma: A potent biomarker predicting lymph node metastasis.
PG  - 345-350
LID - 10.4103/0973-1482.177221 [doi]
AB  - OBJECTIVE: Breast cancer is considered as a heterogeneous disease, characterized 
      by different biological and phenotypic features which make its diagnosis and 
      treatment challenging. The CXC chemokine receptor 4 (CXCR4) expression was found 
      to be correlated with poor overall survival in invasive breast carcinoma 
      patients. Here, we sought to investigate the expression levels of the CXCR4-CXC 
      chemokine ligand 12 (CXCL12) chemokine axis and their association with 
      clinicopathologic features and lymph node metastasis in invasive breast 
      carcinoma. MATERIALS AND METHODS: The expression of the CXCR4-CXCL12 chemokine 
      axis and metastasis-related genes (E-cadherin and matrix metalloproteinase 2 
      [MMP2]) was measured by quantitative real-time-polymerase chain reaction. The 
      correlation with various clinicopathologic parameters was analyzed. RESULTS: We 
      found upregulation of the CXCR4-CXCL12 chemokine axis in invasive breast 
      carcinoma samples compared with normal adjacent tissues. Moreover, we observed 
      that upregulation of this chemokine axis was correlated with tumor stages and 
      lymph node metastasis of breast tumors. Interestingly, this correlation was 
      affected by the expression of human epidermal growth factor receptor 2/neu. There 
      is also a significant correlation between the expression levels of CXCR4-CXCL12 
      axis and metastasis-related genes (E-cadherin and MMP2) in tumor samples with 
      advanced stages of metastasis. CONCLUSION: These results suggest a key role for 
      the CXCR4-CXCL12 chemokine axis in breast cancer progression and highlight the 
      prognostic importance of this chemokine axis for breast cancer survival.
FAU - Dayer, Reza
AU  - Dayer R
AD  - Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares 
      University, Tehran, Iran.
FAU - Babashah, Sadegh
AU  - Babashah S
AD  - Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares 
      University, Tehran, Iran.
FAU - Jamshidi, Shirin
AU  - Jamshidi S
AD  - Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares 
      University, Tehran, Iran.
FAU - Sadeghizadeh, Majid
AU  - Sadeghizadeh M
AD  - Department of Molecular Genetics, Faculty of Biological Sciences, Tarbiat Modares 
      University, Tehran, Iran.
LA  - eng
PT  - Journal Article
PL  - India
TA  - J Cancer Res Ther
JT  - Journal of cancer research and therapeutics
JID - 101249598
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Chemokine CXCL12)
RN  - 0 (Receptors, CXCR4)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Biomarkers, Tumor
MH  - Breast Neoplasms/*genetics/mortality/*pathology
MH  - Chemokine CXCL12/*genetics/metabolism
MH  - Female
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Lymphatic Metastasis
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Receptors, CXCR4/*genetics/metabolism
MH  - Tumor Burden
MH  - Up-Regulation
OTO - NOTNLM
OT  - CXC chemokine receptor 4-CXC chemokine ligand 12 chemokine axis
OT  - invasive breast carcinoma
OT  - lymph node metastasis
OT  - prognosis
COIS- There are no conflicts of interest.
EDAT- 2018/03/09 06:00
MHDA- 2018/08/31 06:00
CRDT- 2018/03/09 06:00
PHST- 2018/03/09 06:00 [entrez]
PHST- 2018/03/09 06:00 [pubmed]
PHST- 2018/08/31 06:00 [medline]
AID - JCanResTher_2018_14_2_345_177221 [pii]
AID - 10.4103/0973-1482.177221 [doi]
PST - ppublish
SO  - J Cancer Res Ther. 2018 Jan-Mar;14(2):345-350. doi: 10.4103/0973-1482.177221.